.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
US Department of Justice
McKesson
UBS
Harvard Business School
Dow
Medtronic
Johnson and Johnson
McKinsey
Cantor Fitzgerald

Generated: November 19, 2017

DrugPatentWatch Database Preview

ARIXTRA Drug Profile

« Back to Dashboard

Which patents cover Arixtra, and what generic Arixtra alternatives are available?

Arixtra is a drug marketed by Mylan Ireland Ltd and is included in one NDA.

The generic ingredient in ARIXTRA is fondaparinux sodium. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fondaparinux sodium profile page.

Pharmacology for ARIXTRA

Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Ireland Ltd
ARIXTRA
fondaparinux sodium
INJECTABLE;SUBCUTANEOUS021345-001Dec 7, 2001APRXYesYes► Subscribe► Subscribe► Subscribe
Mylan Ireland Ltd
ARIXTRA
fondaparinux sodium
INJECTABLE;SUBCUTANEOUS021345-004May 28, 2004APRXYesYes► Subscribe► Subscribe► Subscribe
Mylan Ireland Ltd
ARIXTRA
fondaparinux sodium
INJECTABLE;SUBCUTANEOUS021345-002May 28, 2004APRXYesYes► Subscribe► Subscribe► Subscribe
Mylan Ireland Ltd
ARIXTRA
fondaparinux sodium
INJECTABLE;SUBCUTANEOUS021345-003May 28, 2004APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ARIXTRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Ireland Ltd
ARIXTRA
fondaparinux sodium
INJECTABLE;SUBCUTANEOUS021345-001Dec 7, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Covington
Mallinckrodt
Julphar
Argus Health
QuintilesIMS
Teva
Harvard Business School
Baxter
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot